Overall, these data show that patients who had the worst response to endocrine therapy (defined as progressive disease) had significantly lower PEDF expression than those who had the best response to endocrine therapy (defined as complete response) and that poor clinical response to endocrine therapy is associated with PEDF deficiency in primary breast carcinomas. This evidence concerns the gene SERPINF1 and breast carcinoma.